- Home
- FLNT vs NRBO Comparison
FLNT vs NRBO Comparison
Compare FLNT & NRBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNT
- NRBO
- Stock Information
- Founded
- FLNT 2010
- NRBO N/A
- Country
- FLNT United States
- NRBO United States
- Employees
- FLNT N/A
- NRBO N/A
- Industry
- FLNT Advertising
- NRBO Biotechnology: Pharmaceutical Preparations
- Sector
- FLNT Consumer Discretionary
- NRBO Health Care
- Exchange
- FLNT Nasdaq
- NRBO Nasdaq
- Market Cap
- FLNT 49.6M
- NRBO 27.9M
- IPO Year
- FLNT N/A
- NRBO N/A
- Fundamental
- Price
- FLNT $3.04
- NRBO $2.80
- Analyst Decision
- FLNT Hold
- NRBO Strong Buy
- Analyst Count
- FLNT 1
- NRBO 1
- Target Price
- FLNT $4.00
- NRBO $10.00
- AVG Volume (30 Days)
- FLNT 13.8K
- NRBO 35.4K
- Earning Date
- FLNT 11-19-2024
- NRBO 11-07-2024
- Dividend Yield
- FLNT N/A
- NRBO N/A
- EPS Growth
- FLNT N/A
- NRBO N/A
- EPS
- FLNT N/A
- NRBO N/A
- Revenue
- FLNT $263,700,000.00
- NRBO N/A
- Revenue This Year
- FLNT N/A
- NRBO N/A
- Revenue Next Year
- FLNT $13.16
- NRBO N/A
- P/E Ratio
- FLNT N/A
- NRBO N/A
- Revenue Growth
- FLNT N/A
- NRBO N/A
- 52 Week Low
- FLNT $2.31
- NRBO $2.08
- 52 Week High
- FLNT $4.80
- NRBO $6.75
- Technical
- Relative Strength Index (RSI)
- FLNT 50.06
- NRBO 49.43
- Support Level
- FLNT $2.91
- NRBO $2.41
- Resistance Level
- FLNT $3.11
- NRBO $2.86
- Average True Range (ATR)
- FLNT 0.16
- NRBO 0.29
- MACD
- FLNT -0.01
- NRBO 0.02
- Stochastic Oscillator
- FLNT 29.55
- NRBO 54.93
About FLNT Fluent Inc.
Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers they are seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products & Services, Media & Entertainment, Health & Wellness, Staffing & Recruitment and Retail & Consumer.
About NRBO NeuroBo Pharmaceuticals Inc.
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.